Teva cleared in French switched drug packaging investigation

The French pharmaceutical authorities head has said that there were no deaths because of the wrong pills packaged in a heart failure treatment.

The switched packaging affair in France involving Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) treatments has ended, at least as far as France's National Agency for the Safety of Medicines and Health Products (MSNA) is concerned. MSNA has concluded that all possible steps had been taken to protect the health of the patients.

The affair began two weeks ago when it was found that the packaging of drugs for sleep disorder Zopiclone had been switched with Furosemide, a drug for treating heart failure.

In the days that followed suspicions grew that the switched packaging might have been related to a number of deaths. However, MSNA head Dominic Maraninchi has now said, "There are people who died while on Furosemide not because of Furosemide, thankfully. There are no victims."

Maraninchi added that the inspection of Teva's factory has been completed and no instances of switched packaging was found. MSNA's website says that by yesterday 2,374 packages had been checked (over 70,000 tablets) and everything was in order. He insisted that everyone taking the medication can carry on doing so without any concerns.

At the same time the police investigation continues. When asked if the switched packaging was deliberate tampering, Maraninchi responded that at this stage all scenarios were being considered.

Published by Globes [online], Israel business news - www.globes-online.com - on June 21, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters